BioAngels

Investors meet BioEntrepreneurs

BioAngels is an exclusive matchmaking concept for private investors such as business angels, wealthy individuals, family offices and conventional venture capital investors determined to invest in life sciences & health technology.

Matchmaking

We introduce private investors to selected, innovative start-up projects at an early stage. 

BioEntrepreneurs planning a spin-off or start-up in search of investors can apply with us to present their business idea to our BioAngels. The presenting teams will be prepared by us to submit all relevant information needed for deciding on an investment in an appropriate manner.

Focus on health care sector

Our circle of investors is interested in participating in the following areas:

  •     Innovative drug development
  •     New diagnosis procedures
  •     Big data & digital health
  •     New drug technologies and approaches to regenerative drugs
  •     Innovative platform technologies and services

     

    „On the BioAngels Pitch Day, it is easy to talk to the teams. That would be harder on large investment conferences. I also greatly appreciate the exchange with the other investors.“
    Dr. Hubert Birner, TVM Capital

     

    „The preparation by the team of BioM was very good and intensive. The criticizing feedback has helped us tailor our presentation to the demands of investors.“
    Dr. Kathrin Ladetzki-Baehs, adivo.


More about this topic

BIO-Europe 2024 in Stockholm, Sweden: Meet us at the German Pavilion!

BIO-Europe 2024: Meet us at the Ger­man Pavil­ion!This fall, BIO-Europe re­turns for an en­rich­ing face-to-face ex­per­i­ence, and we're…

SciRhom secures EUR 63 million in Series A financing round for antibody therapy against autoimmune diseases

Martin­sried-based start-up SciRhom has raised €63 mil­lion in a Ser­ies A fin­an­cing round to ad­vance its iRhom2-tar­geted an­ti­body…

Electrochaea GmbH is strategic Partner in Canadian 3rd generation renewable natural gas production

Elec­tro­chaea GmbH from Planegg/München will be in­volved in feas­ib­il­ity study of a pro­ject aimed at pro­du­cing 3rd gen­er­a­tion…

Dr. Petra Burgstaller
Dr. Petra Burgstaller

Incubation & MAxL Co-Lead, Portfolio Management


Christina Enke-Stolle
Christina Enke-Stolle

Incubation & MAxL Co-Lead, Partnership Management